Note: Descriptions are shown in the official language in which they were submitted.
CA 02248854 1998-08-31
WO 98/1420(1 PCT/US96/16213
THE REGULATION OF APPETITE, BODY WEIGHT AND ATHLETIC FUNCTION WITH MATERIALS
DERIVED FROM
CITRUS VARIETIES
INVENTOR: Dennis Jones
1 TECHNICAL FIELD
2 The present invention relates to the use of materials derived from Citrus
plants in
s inducing weight loss, improving physical performance and increasing muscle
mass.
4 REFERENCES TO BACKGROUND ART
s Arner, P., 1993, Adenosine, prostaglandins and phosphodiesterase as targets
for
6 obesity pharmacotherapy. Int. J. Obesity, 17, S57 - 560.
Astrup, A., 1986, Thermogenesis in human brown adipose tissue and skeletal
muscle
s induced by sympathicomimetic stimulation. Acta Endocrinol. Suppl., 278, 1 -
32.
Astrup, A., Lundsgaard, C., Madsen, 1. and Christensen, N.J., 1985, Enhanced
1 o thermogenic responsiveness during chronic ephedrine treatment in man. Am.
J. Clin. Nutr.,
11 42, 83 - 94.
12 Astrup, A., Madsen, J., Holst, J.J. and Christensen, N.J., 1986, The effect
of chronic
1 s ephedrine treatment on substrate utilization, the sympathoadrenal
activity, and energy
14 expenditure during glucose-induced thermogenesis in man. Metabolism, 35,
260 - 265.
15 Astrup, A., Toubro, S., Cannon, S., Hein, P. and Madsen, J., 1990a,
Thermogenic,
16 metabolic and cardiovascular effects of a sympathicomimetic agent,
ephedrine. Curr. Ther.
m Res., 48, 1087 - 1100.
1e Astrup, A., Toubro, S., Cannon, S., Hein, P. Breum, L. and Madsen, J.,
1990b,
19 Caffeine: a double-blind, placebo-controlled study of its thermogenic,
metabolic and
2o cardiovascular effects in healthy volunteers. Am. J. Clin. Nutr., 51, 759 -
767.
2 z Astrup, A., Breum, L., Toubro, S., Hein, P. and Quaade, F., 1992a, The
effect and
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and
placebo in
2 obese subjects on an energy restricted diet. A double blind trial. Int. J.
Obesity, 16, 169-277.
s Astrup, A., Buemann, B., Christensen, N.J., Toubro, S., Thorbek, G., Victor,
O.J. and
4 Quaade, F., 1992b, The effect of ephedrine/caffeine mixture on energy
expenditure and body
s composition in obese women. Metabolism, 41, 686 - 688.
Astrup, A., Breum, L., Toubro, S., Hein, P. and Quaade, F., 1992c, Ephedrine
and
weight loss. Int. J. Obesity, 16, 715.
s Astrup, A., Toubro, S., Christensen, N.J. and Quaade, F., 1992d,
Pharmacology of
a thermogenic drugs. Am. J. Clin. Nutr., 55, 2465 - 248S.
~o Astrup, A. and Toubro, S., 1993, Thermogenic, metabolic, and cardiovascular
m responses to ephedrine and caffeine in man. Int. J. Obesity, 17, S41 - 544.
12 Bown, D., 1995, The Encyclopedia of Herbs & Their Uses. Dorling Kindersly,
13 London.
i4 Breum, L., Pedersen, J.K., Ahlstrom, F. and Frimodt-Moller, J., 1994,
Comparison of
1 s an ephedrine/caffeine combination and dexfenfluramine in the treatment of
obesity. A
16 double-blind multi-center trial in general practice. Int. J. Obesity, 18,
99 - 103.
m Buemann, B., Marckmann, P., Christensen, N.J. and Astrup, A., 1994, The
effect of
1 a ephedrine plus caffeine on plasma lipids and lipoproteins during a 4.2
MJ/day diet. Int. J.
19 Obesity, 18, 329 - 332.
2o Court, J.M., Dunlop, M.E. and Boulton, T.J., 1974, Effect of ephedrine in
ketotic
21 hypoglycaemia. Arch. Dis. Child., 49, 63 - 65.
22 Daly, P., Krieger, D., Dulloo, A., Young, J. and Landsberg, L., 1993,
Ephedrine,
23 caffeine and aspirin: safety and efficacy for treatment of human obesity.
Int. J. Obesity, 17,
24 S73 - 578.
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 Drug Facts and Comparisons, 1995, Facts and Comparisons, St. Louis.
2 Dulloo, A.G. and Miller, D.S., 1986, The thermogenic properties of
ephedrine/methylxanthine mixtures: human studies. Int. J. Obes., 10, 467 -
481.
Q Dulloo, A.G. and Miller, D.S., 1987, Aspirin as a promoter of ephedrine-
induced
thermogenesis: potential use in the treatment of obesity. Am. J. Clin. Nutr.,
45, 564 - 569.
Dulloo, A.G. and Miller, D.S., 1989, Ephedrine, caffeine and aspirin:
"over-the-counter" drugs that interact to stimulate thermogenesis in the
obese. Nutrition S,
s 7-9.
Dulloo, A.G., Seydoux, J. and Girardier, L., 1991, Peripheral mechanisms of
1 o thermogenesis induced by ephedrine and caffeine in brown adipose tissue.
Int. J. Obes., 15,
m 317 - 326.
12 Dulloo, A.G., 1993, Ephedrine, xanthines and prostaglandin inhibitors:
actions and
13 interactions in the stimulation of thermogenesis. Int. J. Obesity, 17, 535 -
540.
14 Font Quer, P., (1982), "Plantes Medicinales; e1 Dioscorides renovado".
Editorial
Labor S.A., Madrid.
16 Gahart, B.L., 1985, Intravenous medications; a Handbook for Nurses and
other allied
i ~ health professionals. 4th Edition, The C. V. Mosby Company, 200 - 201.
1 a Geissler, C., 1993, Effects of weight loss, ephedrine and aspirin on
energy expenditure
19 in obese women. Int. J. Obesity, 17, S45 - 548.
2 o Gerard, J., 1597, The Herball or Generall Historie of Plantes, John
Norton, London.
2i Second Edition enlarged and amended by Thomas Johnson, 1633, and reprinted
1636 [Note:
22 translation ofDodoens' Stirpium Historiae Pemptades Sex, Antwerp, 1583].
2 s Govoni, L.E. and Hayes, J.E., 1985, Drugs and Nursing Implications.
2 4 Appleton-Century-Crofts, Norwalk.
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
z Grieve, M., 1992, A Modern Herbal. Dorset Press, New York.
2 Hopkins, D.F., Cotton, S.J. and Williams, G., 1993, Effective treatment of
insulin-induced edema using ephedrine. Diabetes Care, 16, 1026 - 1028.
4 Huang, K.C., 1993. The Pharmacology of Chinese Herbs, 173. CRC Press, Boca
Raton.
Jonderko, K. and Kucio, C., 1991, Effect of anti-obesity drugs promoting
energy
7 expenditure, yohimbine and ephedrine, on gastric emptying in obese patients.
Aliment.
s Pharmacol. Ther., 5, 413 - 418.
9 Jones, D. and Egger, T.E., 1993, Use of herbs containing natural source
ephedrine
t o alkaloids in weight loss programmes. /nt. J. Obes., 17, 581.
ii Kaats, G.R. and Adelman, J.A., 1994, Effects of a multiple herbal
formulation on body
12 composition, blood chemistry, vital signs, and self reported energy levels
& appetite control.
13 Int. J. Obesity, 18 (Supp. 2), S 145. Also personal communication.
19 Kowalchik, C., and Hylton, W., 1987, Rodale's Illustrated Encyclopaedia of
Herbs.
Rodale Press, Emmaus, Pennsylvania
16 Krieger, D.R., Daly, P.A., Dulloo, A.G., Ransil, B.J., Young, J.B. and
Landsberg, L.,
1 ~ 1990, Ephedrine, caffeine and aspirin promote weight loss in obese
subjects. Trans. Assoc.
is Am. Physicians, 103, 307 - 312.
19 Landsberg, L. and Young, Y.B., 1993, Sympathoadrenal activity and obesity:
2 o physiological rationale for the use of adrenergic thermogenic drugs. Int.
J. Obesity, 17,
21 S29-S34.
22 Lewis, W.H. and Elvin-Lewis, M.P.F., 1977, Medical Botany. John Wiley &
Sons,
2 s New York.
24 Li Shih-Chen, 1596, Ben Cao Kong Mu, Peking, China.
Lowe, F.C. and Jarow, J.P., 1993, Placebo-controlled study of oral terbutaline
and
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 pseudoephedrine in management of prostaglandin E1-induced prolonged
erections. Urology,
2 42, 51 - 54.
3 Malchow-Moller, A., Larsen, S., Hey, H., Stokholm, K.H., Juhl, E. and
Quaade, F.,
4 1980, EfI'ekten of Helsingor-pillen i behandlingen of adipositas. En
kontrolleret klinisk
s undersogelse. Ugeskr. Laeger., 142, 1496 - 1499.
Malchow-Moller, A., Larsen, S., Hey, H., Stokholm, K.H., Juhl, E. and Quaade,
F.,
1981, Ephedrine as an anorectic: the story of the'Elsinore pill'. Int. J.
Obes., 5, 183 - 187.
s Matthews, W.B., 1983, The autonomic nervous system, in Oxford Textbook of
9 Medicine, Ed. Weatherall, D.J., Ledingham, J.G.G. and Warren, D.A., 21.23,
Oxford
1 o University Press, Oxford, New York, Toronto.
Molnar, D., 1993, Effects of ephedrine and aminophylline on resting energy
i2 expenditure in obese adolescents. Int. J. Obesity, 17, S49 - 552.
13 Moritz, O, 1953, Einfiihrung in die algemeine Pharmakognosie. 2nd Edition,
Jena, 305
14 - 306.
is Munson, P.L. (Ed.), 1995, principles of pharmacology; basic concepts and
clinical
16 applications. Chapman & Hall, New York.
m Nielsen, B., Astrup, A., Samuelsen, P., Wengholt, H. and Christensen, N.J.,
1993,
1 a Effect of physical training on thermogenic responses to cold and ephedrine
in obesity. Int. J.
Z9 Obesity, 17, 383 - 390.
2 o Ou Ming, 1989, Chinese-English Manual of Common-Used in Traditional
Chinese
21 Medicine; Guangdong Science & Technology Publishing House and Joint
Publishing (H.K.)
22 Co., Ltd., Hong Kong.
2s Pasquali, R., Baraldi, G., Cesari, M.P., Melchionda, N., Zamboni, M.,
Stefanini, C. and
24 Raitano, A., 1985, A controlled trial using ephedrine in the treatment of
obesity. Int. J. Obes.,
2 s 9, 93 - 98.
CA 02248854 1998-08-31
WO 98/14200 PCTIUS96/16213
1 Pasquali. R., Cesari, M.P., Melchionda, N., Stefanini, C., Raitano, A. and
Labo, G.,
2 1987a, Does ephedrine promote weight loss in low-energy-adapted obese women?
/nt. J.
3 Obes., 1 l, I63 - 168.
Pasquali. R., Cesari, M.P., Bestighi, L., Melchionda, N. and Balestra, V.,
1987b,
s Thermogenic agents in the treatment of human obesity: preliminary results.
Int. J. Obes., 11,
Suppl. 3, 23 - 26.
Pasquali, R., Casimirri, F., Melchionda, N., Grossi, G., Bortoluzzi, L.,
Morselli Labate,
s A.M., Stefanini, C. and Raitano, A., 1992, Effects of chronic administration
of ephedrine
during very-low-calorie diets on energy expenditure, protein metabolism and
hormone levels in
s o obese subjects. Clin. Sci., 82, 85 - 92.
1 z Pasquali, R. and Casimirri, F., 1993, Clinical aspects of ephedrine in the
treatment of
z2 obesity. Int. J. Obesity, 17, S65 - 568.
13 Quaade, F., Astrup, A., Breum, L., Toubro, S. and Hein, P., 1992, Effekten
of en
14 efedrinkoffein-kombination som understottelse of en affedningsdiaet. En
randomiseret,
z5 placebokontrolleret, dobbeltblind undersogelse. Ugeskr. Laeger., I54, 1258 -
1263.
16 Reid, D.P., 1986, Chinese Herbal Medicine. Shambhala, Boston.
m Reynolds, J.E.F., Ed., 1982, Martindale; the Extra Pharmacopoeia, 28th
Edition. The
1 a Pharmaceutical Press, London.
19 Roed, P., Hansen, P.W., Bidstrup, B., Kaern, M., Helles, A. and Petersen,
K.P., 1980,
2 o Helsingor-slankepiller. En kontrolleret klinisk undersogelse i
almenpraksis. Ugeskr. Laeger.,
21 142, 1491 - 1495.
22 Southon, LW. and Buckingham, J., (Eds.), 1989, Dictionary of Alkaloids, 1st
Edition,
2 s Main Work (Chapman & Hall). See also Dictionary of Organic Compounds,
1982, Sth
2 4 Edition, Main Work (Chapman & Hall).
25 Stokholm, K.H. and Hansen, M.S., 1983, Lowering of serum total T3 during a
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 conventional slimming regime. Int. J. Obes., 7, 195 - 199. ,
2 Streeten, D.H., 1975, The role of posture in idiopathic oedema. S. Afr. Med.
J., 49,
s 462 - 464.
4 Stuart, M., 1979, The Encyclopaedia of Herbs and Herbalism. Orbis Publishing
s Limited, London.
Toubro, S., Astrup, A., Breum, L. and Quaade, F., 1993, Safety and efficacy of
long-term treatment with ephedrine, caffeine and an ephedrine/caffeine
mixture. Int. J.
s Obesity, 17, S69 - S72.
9 Tyler, V.E., 1982, The Honest Herbal - A sensible guide to the use of herbs
and
i o related remedies. George F. Stickley, Philadelphia.
11 Vallerand, A., 1993, Effects of ephedrine/xanthines on thermogenesis and
cold
i2 tolerance. Int. J. Obesity, 17, S53 - 556.
i3 Wheaton, T.A. and Stewart, L, 1970, The distribution of tyramine, N-
methyltyramine,
14 hordenine, octopamine and synephrine in higher plants. Lloydia, 33, 244 -
254.
15 Wichtl, M., Ed., 1994, Herbal Drugs and Phytopharmaceuticals, Trans.
Bissett, N.G.,
16 CRC Press, Boca Raton.
m Yang, Y.T. and McElligott, M.A., 1989, Multiple actions of beta-adrenergic
agonists
la on skeletal muscle and adipose tissue. Biochem. J., 261, 1 - 10.
19 BACKGROUND ART
2 o It has long been known that natural and synthetic substances may
facilitate weight loss
21 in those who are overweight or obese. Such substances as have found utility
in this respect
22 may act by a variety of mechanisms. For example, some such substances act
by mimicking the
2 s effects of endogenous neurotransmitters, and are capable of directly
replacing these
2 4 neurotransmitters in their actions on receptors. This, in turn, leads to
increased activity of the
2 s cells which possess the receptors. Where the receptors concerned are
normally responsive to
7
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
l the endogenous hormones adrenaline (epinephrine) and noradrenaline
(norepinephrine), which
2 mediate the activities of the sympathetic nervous system, such substances
are termed
direct-acting sympathicomimetic agents. Typical examples are the amphetamines.
Other
4 substances that produce similar effects on the sympathetic nervous system do
so by stimulating
s the release of the endogenous hormones adrenaline and noradrenaline, and are
thus termed
indirect-acting sympathicomimetic agents. Ephedrine is a typical example of an
indirect-acting
sympathicomimetic agent. The term adrenergic may also be used, and is
synonymous with the
s term sympathicomimetic. Such substances may also be referred to as agonists,
where the
name agonist is qualified by a descriptor of the receptor stimulated, for
example, a
z o beta-agonist.
11 While the formal distinction between direct-acting and indirect-acting
12 sympathicomimetic action is clear, it is realized that many substances
which act by causing
13 sympathetic stimulation do so by both mechanisms, depending on intake
levels and the
14 receptors involved. Thus amphetamines act mainly directly, but also have
some indirect
1 s actions, while ephedrine acts indirectly, but if given in higher dosage,
may also stimulate
16 receptors directly, particularly in the brain. It has been demonstrated
that the main perceived
1 ~ actions of sympathicomimetic agents depend both on their differing
specificities for the various
z s receptors and on the pharmacokinetic behaviors of the agents in the body.
I9 Thus the amphetamines, which are direct agents and readily cross the blood-
brain
2 o barrier, mainly cause central nervous system stimulation, while ephedrine,
and particularly
21 pseudoephedrine, are indirect agents which do not cross the blood-brain
barrier so readily, and
22 thus are mainly seen to exert peripheral effects.
23 Another class of substances of value in assisting weight loss modulates
other
2 4 neurotransmitters, namely those involved in serotoninergic systems, and
particularly
2s 5-hydroxytryptamine (S-HT; otherwise known as serotonin) itself. These
substances, of which
CA 02248854 1998-08-31
WO 98/14200 PCTlUS96/16213
1 fenfluramine and its optical isomer, dexfenfluramine, are typical, act by
preventing the
2 re-uptake of serotonin into storage granules in neurones. Levels of 5-HT in
the synaptic gap
s thus remain elevated for longer periods, exciting receptors on responsive
cells to greater
activity.
s Other aids to weight loss have been proposed, such as substances which
prevent the
6 absorption of nutrients from the digestive system, but the value of such
approaches is minimal,
and in general, the accepted substances of value in weight loss act by
modulating
s neurotransmitter function in the central nervous system or peripherally.
Substances which modulate neurotransmitter function in the central nervous
system are
1 o known to act by increasing the availability of catecholamines, in
particular noradrenaline, in
1 z certain areas of the brain, thus resulting in perceived suppression of
hunger. By suppressing
12 hunger, less food is eaten, and caloric intake is lowered. Examples of such
substances include
1s phenylpropanolamine, phentermine and the amphetamines.
14 Substances which act by increasing the availability of 5-hydroxytryptamine
(serotonin),
1 s on the other hand, are known to increase perceptions of satiety. An
example of such a
16 substance is dexfenfluramine
m Irrespective of mechanism, substances of either of these types result in
reduced food
1$ intake. But their use can be attended by various unwanted effects
characteristic of interference
19 with other hormone-regulated systems in the body. It has furthermore been
noted that the
2 o effects of these types of substances are transient, requiring
progressively greater dosage to
21 elicit desired effects, until the body finally becomes unresponsive. This
progressive decrease in
22 sensitivity is termed tachyphylaxis.
23 More recently, attention has been focused on ephedrine, which was
originally thought
24 to suppress the hunger center in the brain. However, during the last 30
years, research has
2 s shown that ephedrine acts mainly by stimulating thermogenesis. That is, it
increases the
9
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
z metabolic rate and stimulates lipolysis (fat breakdown).
2 The effect of ephedrine on the peripheral metabolic rate is derived from
actions on
s energy-generating tissues combined with stimulation of the release of fat
from stored fat
9 depots (adipose tissue). This not only increases the generation of energy
but also increases the
s availability of substrates to be utilized for this energy generation. A
valuable consequence of
6 these two actions is the sparing of body protein, which in certain cases,
depending on the
composition of the diet, may even result in a gain of body protein (anabolic
effect).
s The effects of ephedrine can often be intensified by concomitant use of
methylxanthines such as caffeine.
1 o Empirical studies have shown that ephedrine, whether as the pure substance
or in the
11 farm of Ephedra herb:
i2 (a) Improves rates of weight loss in patients on low calorie diets, spares
lean body
is mass (Pasquali et al., 1992; Kaats and Adelman, 1994), increases the
14 proportion of fat in the weight lost (Astrup et al., 1992b) and prevents
the
15 decline in Resting Metabolic Rate usually seen with reduced caloric intake
(Astrup et al., 1992b; Astrup and Toubro, 1993).
1 ~ (b) Gives results, through increased thermogenesis and stimulation of
lipolysis (fat
1 s breakdown) at dosage levels below those required to elicit stimulant or
hunger
i9 suppressant effects (Astrup and Toubro, 1993).
2 0 (c) Shows synergism in the effects on weight loss when combined with
caffeine
21 (Daly et al., 1993; Astrup and Toubro, 1993).
22 (d) Is not associated with significant adverse effects. Thermogenic effects
became
2s more pronounced as treatment continues (Astrup et al., 1985, 1986) while
2 4 initial adrenergic effects (which are not pronounced) exhibit
tachyphylaxis and
2 s rapidly disappear (Astrup et al., 1992a}.
~o
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 It has even been suggested that ephedrine may be an example of a trace
substance that
2 belongs in the human diet, and that it provides an opportunity to attack
obesity at a level that
s is close to causative (Landsberg and Young, 1993}.
4 Based on the clinical observations, ephedrine may therefore be considered an
ideal
pharmacological aid in the treatment of obesity.
6 Though it has some central stimulant effect, and thus mediates suppression
of hunger,
ephedrine's main mode of action appears to be peripheral and, in part,
causative since it offsets
a the decline in metabolic rate that normally occurs on caloric restriction.
The decline in
metabolic rate that accompanies caloric restriction, therefore, is well known
to those schooled
z o in the art to defeat the initial weight loss benefits associated with
caloric restriction. The body,
11 in effect, recognizes the "starvation" period, becomes more efficient in
utilizing caloric
i2 resources, and simply waits until normal caloric intake is resumed. This
explains the "plateau"
13 effect seen in caloric restriction diets. When normal caloric intake is
resumed, the body's
14 increased efficiency actually restores the fat lost in the caloric
restriction period. This is
commonly known as the "yo-yo dieting" effect.
16 The thermogenic action which results from ephedrine's effects on metabolic
rate and
17 lipolysis persists throughout its use period, and may intensify as use
continues.
1e Ephedrine's classical adrenergic actions, which are undesirable in a weight
loss
19 context, cease rapidly due to tachyphylaxis.
2 o The classical uses of ephedrine and pseudoephedrine for a variety of
conditions are
21 well illustrated by reference to standard works on Pharmacology and
Therapeutics. For
22 example, Govoni and Hayes (1985) describe use of ephedrine as a
decongestant in allergic
2 s rhinitis, sinusitis and chronic asthma (often combined for such
indications with theophylline, a
24 methylxanthine closely related to caffeine in structure and effect), in the
treatment of
2 s narcolepsy, to combat hypotensive states (especially those associated with
spinal anesthesia),
ii
CA 02248854 1998-08-31
WO 98/14200 PCT/IJS96/16213
1 in the management of enuresis, as adjunctive therapy for myasthenia gravis,
as a mydriatic, as
2 temporary support of ventricular rate in Adams-Stokes syndrome, to relieve
dysmenorhoea,
and for management of peripheral edema secondary to diabetic neuropathy.
Streeten ( 1975)
4 adds idiopathic edema to the list of conditions where ephedrine (150 - 200
mg per day) has
s beneficial activity, and other uses verified have included ketotic
hypoglycaemia (Court et al.,
6 1974), urological syndromes caused by prostaglandin E, (Lowe and Jarow,
1993) and
insulin-induced edema (Hopkins et al., 1993). Matthews (1983) discusses the
action of
s ephedrine on the internal sphincter of the bladder and urethra in relation
to its use in treating
urinary incontinence. Govoni and Hayes (1985) note that maximum parenteral
dosage should
to not exceed 150 mg/day by sub-cutaneous (s.c.), intramuscuiar (i.m.) or
intravenous (i.v.)
11 routes and comment that unwanted effects (all of which are consequent on
the pharmacology
12 involved) usually only occur with large doses. The same textbook teaches
that
13 pseudoephedrine essentially shares these properties, but is mainly used for
relief of rhinitis in
14 doses up to 240 mg/day for adults; Southon and Buckingham (1989) concur
that
1 s pseudoephedrine and ephedrine have similar pharmacological profiles, but
that
16 pseudoephedrine is less potent.
m Naturally occurrin3 ephedrine is the 1R,2S(-)-erythro form, which is the
most active
1 s pharmacologically. Pseudoephedrine is the threo form.
19 Acting indirectly, the main action of ephedrine is to elicit release of
noradrenaline
2 0 (norepinephrine) from presynaptic sites. This in turn activates both alpha-
and
21 beta-adrenoceptors. The perceived effects on different organs and tissues
depend on the
22 relative proportions of the two types of receptors, which mediate different
responses. At a
2 s basal level, classical pharmacology teaches that alpha-activation results
in contraction of
2 4 smooth muscle (except for intestinal smooth muscle) while beta-activation
causes relaxation of
2 s smooth muscle and stimulation of the myocardium. But this picture is
complicated by the fact
i.~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 that both alpha- and beta-receptors can be subdivided into further types
with differing
2 distributions and sensitivities.
3 At a cellular level, activation of beta-receptors results in stimulation of
adenylate
4 cyclase. This leads to increases in intracellular levels of cyclic adenosine
monophosphate
(cAMP). The precise sequence of events (Munson, 1995) is believed to be:
6 ( 1 ) The beta-agonist binds to the beta-receptor.
(2) The receptor-agonist complex has high affinity for a stimulatory guanine
s nucleotide regulatory protein termed the Gs protein, and binds to this
protein.
9 (3) Formation of the receptor-agonist-Gs complex facilitates the exchange of
1 o guanine diphosphate (GDP) for guanine triphosphate (GTP) on the Gs
protein.
11 (4) The Gs-GTP complex dissociates from the receptor-agonist complex and
then
12 interacts with the catalytic subunit of adenylate cyclase, promoting the
is conversion of adenosine triphosphate to cAMP.
z4 (5) The cAMP activates a cAMP-dependent protein kinase, which can then
15 phosphorylate a variety of intracellular proteins, ultimately leading to a
16 pharmacological response.
z ~ Feedback inhibition control is achieved by phosphorylation of receptor
proteins, which
18 results in their desensitization.
19 Activation of most alpha-2 receptors has an opposite effect, the first step
being
2 o inhibition of adenylate cyclase through a guanine nucleotide regulatory
protein termed Gi.
2 i The Gi protein, by inhibiting the catalytic activity of the adenylate
cyclase, leads to a reduction
22 in cellular levels of cAMP, which decreases the activation of the CAMP-
dependent protein
2 s kinases. However, in some alpha-2 receptors, the Gi protein may act
through other
2 n mechanisms which have not yet been elucidated, but possibly lead to
activation of membrane
2 s calcium channels.
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 The alpha-1 receptors have a different mechanism.. It does not appear to
involve
2 cAMP, but apparently relies instead on diacyl glycerols and inositol-1,4,5-
triphosphate.
s It is readily understood that the beta-receptors can also be further
subdivided based
4 upon their mechanism of action. The known subdivision of beta-receptors into
beta-1, beta-2,
s and beta-3 types is of particular interest for this invention since the beta-
3-receptor is strongly
believed to be responsible for the lipolytic and thermogenic effects of
ephedrine while
interactions with the other two types of beta-receptors are known to control
cardiac effects of
s ephedrine.
Effects on blood pressure, however, are in part due to the stimulation of
alpha-2-
1 o receptors, where such stimulation produces peripheral vasoconstriction.
11 Central nervous system effects of ephedrine appear to depend on activation
both alpha-
12 and beta-receptors (with the exception of beta-3-receptors). The multi-
receptor response to
13 ephedrine is also important in explaining observed synergistic effects of
caffeine on certain
19 actions of ephedrine.
15 The overall response to ephedrine, reflected in.perceived effects, is
governed by the
16 distribution of receptors in terms of types and populations. As an example,
the activation of
1 ~ beta-receptors causes vasodilation of vessels in the heart and skeletal
muscle while
is simultaneous alpha-2-activation results in vasoconstriction in other
vascular beds. This is
z 9 effectively the classical "fight or flight" response, which together with
other metabolic results
2 0 of adrenoceptor activation is intended to put the body into an optimal
state for physical
21 exertion.
22 The metabolic results of adrenoceptor activation also include effects on
iipolysis and
2s thermogenesis. In the case of lipolysis, activation of alpha-2-receptors
inhibits the process,
z 4 while activation of beta-receptors (believed to be the beta-3-subtype)
stimulates lipolysis and
2s at same time, possibly in part due to increased availability of substrate,
induces a thermogenic
i~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 response. The overall response of the adipose tissue thus depends on the
relative proportions
2 of alpha-2 and beta-3 receptors. A high ratio of alpha-2 to beta-3 receptors
would produce a
s comparatively lower thermogenic response than a low ratio. Indeed, the
predicted
diminishment of thermogenic response associated with increasing proportion of
alpha-2
compared to beta-3 receptors may explain why some studies of thermogenic
responses to
6 ephedrine have found two populations: responders and relative non-
responders.
Attention has been paid to the unexpected finding that thermogenic properties
of
a ephedrine do not exhibit tachyphylaxis. Landsberg and Young (1993) adopt the
position that
since the activity of the sympathetic nervous system may be reduced in
obesity, improvement
of sympathetic nervous system activity to normal levels is physiological
rather than
m pharmacological, and that the use of ephedrine in obese persons does nothing
more than
i2 restore normal catecholamine function. In this respect, therefore,
ephedrine differs in no way
13 from the effects of high protein diets or consumption of foods containing
natural thermogenic
14 substances. Lansdberg and Young also suggest that ephedrine may be
particularly useful in
1 s combating the weight gain that usually follows cessation of smoking since
smoking cessation
16 is also associated with impaired catecholamine function.
Dulloo (1993) concurs with Lansdberg and Young's point of view. He notes that
at
z 8 levels compatible with therapeutic doses, ephedrine has little or no
direct agonist activity but
19 mediates its effects via endogenous release of noradrenaline and
adrenaline. Essentially,
2 o therefore, ephedrine does nothing more than increase the efficiency of the
system already in
21 place in the body. He notes that this has potential positive implications
for ephedrine's use in
22 the treatment of obesity, and also explains some of the obscure clinical
observations reported:
2 s 1 ) The fact that tolerance rapidly develops to the very mild
cardiovascular effects of
2 4 ephedrine, but not to its thermogenic effects, suggests that adrenaline
and
2 s noradrenaline released by ephedrine activate the beta-3-adrenoceptors.
i~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 2) The adrenaline released is a preferential agonist for the beta-2-
adrenoceptors which
2 stimulate protein synthesis and thus can counteract loss of lean body mass
during
use of low calorie diets.
In this respect, Pasquali et al. ( 1992) have shown that ephedrine enhances
fat loss in
s diet-restricted obese patients and reduces loss of nitrogen.
6 3) Chronic stimulation of postsynaptic alpha-adrenoceptors by the adrenaline
and
noradrenaline released in response to ephedrine therapy may activate thyroxine
s deiodinases, leading to peripheral conversion of T4 (thyroxine) to T3
9 (triiodothyronine), which may, in turn, increase adrenoceptor sensitivity to
the
1 o thermogenic effects of the catecholamines since T3 is much more active
than T4.
m This mechanism may also partially explain why the thermogenic effect of
ephedrine is
12 increased after chronic administration.
13 4) Single dose studies have shown that skeletal muscle and visceral organs
contribute
14 mOSt of the thermogenic activity after ephedrine administration, with a
minor
is contribution from adipose tissue. These tissues can all be reactivated and
even
16 proliferate in response to chronic catecholamine activation, which may
explain the
1 ~ enhanced thermogenesis seen with prolonged ephedrine treatment.
la Dulloo suggests that ephedrine, with chronic administration, exerts its
effects indirectly
f 9 via adrenaline and noradrenaline and thereby generates its own selectivity
for desirable
2o anti-obesity effects. This is accomplished by the down-regulation of
adrenoceptor types or
21 subtypes associated with unwanted cardiac or pressor effects and with
sustained activation of
22 adrenoceptor types that mediate thermogenesis, lipolysis and protein
retention.
2 s Arner ( 1993) approaches the mechanism of ephedrine action from the
lipolysis aspect.
24 He notes that catecholamines have both lipolytic and antilipolytic effects,
so that at any time
2 s there is a balance between these effects. However, it has been suggested
that lipid metabolism
i~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 in man is mainly controlled by inhibitory modulators, and adenosine has been
shown to reduce
2 the sensitivity of lipolytic beta-adrenoceptors, particularly in
subcutaneous fat depots. Several
3 prostaglandins of the E-type are also potent antilipolytic agents. Thus the
potentiation of the
ephedrine effect by caffeine (which may affect adenosine dynamics) and aspirin
(which can
inhibit prostaglandin synthysis) may not be restricted to the synaptic gap,
but may also extend
6 into the actual fat-mobilizing mechanism.
Dulloo (1993) noted that in early investigations of ephedrine use as an anti-
obesity
a agent, attention focused on the main action , of ephedrine in reducing
appetite (the anorexic
9 effect). It now appears that the thermogenic and lipolytic effects are the
main properties that
1 o make ephedrine so suitable for use as a weight loss aid. Indeed,
significant improvements of
11 rates of weight loss occur at ephedrine dosage levels far below those
required to achieve
i2 detectable main effects, and increasing dosage to the level at which main
effects occur does
Zs not necessarily give better rates of weight loss (Daly et al., 1993).
i4 While the actions of ephedrine makes it an ideal adjunct for regulating and
controlling
i s weight problems, it will be obvious to those skilled in the art that it
may also be useful as an
16 ergogenic aid to improve physical performance. The acute action is to
increase energy
i ~ availability and, thus, increase the capacity for physical exertion, while
the longer-term actions
is result in an increase in muscle mass, particularly when combined with
appropriate diet
19 programs and training exercises. Indeed, Yang and McElligott ( 1989) have
commented that
2 o beta-adrenergic agents may act as very effective anabolic agents when
given over long periods
21 of time. Both the beneficial ergogenic effects and the valuable effects on
weight loss stem
22 from the combination of the effects of ephedrine on lipolysis and its
thermogenic effects. Thus
23 by increasing the rate at which fat is released from body stores
(lipolysis) while simultaneously
24 increasing the metabolic rate (thermogenesis), those wishing to lose weight
may accelerate the
2 s removal of unwanted fat stores.
i7
CA 02248854 1998-08-31
WO 98!14200 PCT/US96/16213
1 At the same time, since the administration of ephedrine means there is
increased
2 availability of substrates (the free fatty acids which are released from the
fat stores) for
3 oxidation, the body has access to greater amounts of energy. The body's use
of these
substrates spares protein that might otherwise be oxidized for energy.
Therefore, the use of
s ephedrine in conjunction with additional favorable circumstances, namely a
high protein intake
6 and an exercise program, will also result in increased availability of amino
acids for
incorporation into protein in the muscle mass.
a From the foregoing, it will be obvious to those skilled in the art that the
agents most
9 suitable for inducing weight loss in those with excess weight, or, for
persons of normal weight,
z o increasing energy availability and/or muscle mass, would be
sympathicomimetic (adrenergic)
11 agents whose mechanism of action is mainly indirect, resembling that of
ephedrine, and whose
z2 pharmacokinetics favor retention of the agents in the periphery rather than
passage into the
13 brain. Agents whose profiles match these requirements would be less likely
to cause central
14 nervous system stimulation under normal conditions of use, but would still
possess enough
1 s central action to suppress the hunger center. The partition in favor of
peripheral tissues would
16 result in increased levels of these agents at the sites of the beta-3-
receptors, which mediate
lipolysis and thermogenesis. It is also widely believed that sympathicomimetic
agents
1 s possessing mainly an indirect mechanism of action would be less likely to
cause unwanted side
19 effects and less likely to result in addictive situations.
2 o Hitherto, the only such agent which has been shown to act in the optimized
ideal
21 fashion has been ephedrine itself. Ephedrine has some drawbacks, however.
It is primarily
22 provided in pharmaceutical forms which allow quick release in the body for
the alleviation of
23 acute respiratory ailments whereas, for the purposes of inducing lipolysis
and thermogenesis, a
29 slower release is desirable. Furthermore, many of those who are overweight
prefer not to use
2 s agents which are presented as drugs. In addition, for a variety of health
conditions, such use
i~
CA 02248854 1998-08-31
WO 98/14200 PCTIUS96/16213
1 will often be contraindicated because of the risk of potentially hazardous
side effects, which
2 risk could be increased because of the weight problem.
s Prior to this invention, those wishing to avail themselves of natural
products for
4 eliciting weight loss or increasing muscle mass have had no choice other
than to use products
s containing Ephedra herb (Ephedraceae}, which contains ephedrine together
with related
alkaloids. However, because of concerns about the use of Ephedra herb
products, many do
not avail themselves of this opportunity.
s The provision of a natural product that acts in the ideal fashion noted
above would
9 therefore provide major benefits to those seeking to lose weight or improve
their physical
z o fitness, or both, and would be especially useful to those who prefer not
to take either drug-like
m products or natural products containing ephedrine alkaloids.
12 SUMMARY OF THE INVENTION
1 s The present invention relates to the discovery that certain plants contain
adrenergic
14 amines of the group consisting of synephrine, hordenine, octopamine,
tyramine and N-
1 s methyltyramine that are useful to assist in weight loss, adding muscle
mass, and/or increasing
16 physical performance. More particularly, the present invention relates to
the discovery that
m useful and exploitable levels of these adrenergic amines only occur in plant
species of Citrus.
~ s In still greater detail, the invention relates to the discovery that these
useful levels only
19 occur in parts of the plant that are not normally eaten, including the
leaves and bark, or in the
2 o fruit in certain stages of maturity. In yet fizrther detail, the invention
relates to a composition
21 in which the plant parts are used in various forms to provide
therapeutically effective doses of
22 these adrenergic amines and to a composition in which the adrenergic amines
are extracted
2 3 from the plant parts using methods well known to those schooled in the
art.
24 In further detail, the invention relates to the use of the composition to
stimulate beta-
/9
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 receptors in a predominantly indirect fashion thereby stimulating
thermogenesis, increased
2 metabolic rate and lipolysis. In yet additional detail, the invention
relates to the use of the
s composition to control appetite by suppressing hunger.
4 In further detail, the composition of the invention has utility in
regulating or treating
s weight problems as well as increasing vitality, energizing, and in the long
term increasing
6 muscle mass.
In still further detail, the amounts of the adrenergic amines of this
invention needed to
a be effective can be as low as one mg ingested three times daily, and the low
dosage effective
range is from one to five mg ingested up to 3 or 4 times daily. Still further,
the preferred use
of this invention is to administer single doses of from 8 to 30 mg up to 4
times daily, making a
11 total daily dose of about 100 to 120 mg per day.
i2 In a further aspect, the present invention relates to a method for weight
loss and a
13 method for ergogenesis to aid in improved physical performance and to aid
in adding lean
14 muscle mass to the body.
An object of the present invention is to provide a composition containing an
effective
16 weight control/weight loss amount of at least one of the group of
adrenergic amines
1 ~ synephrine, hordenine, octopamine, tyramine and N-methyltyramine.
1s Another object of the present invention is to provide a composition
containing an
19 effective amount of at least one of these adrenergic amines to stimulate
the addition of lean
2 o muscle mass.
21 Yet another object of the present invention is to provide a composition
containing an
22 effective amount of at least one of these adrenergic amines to enhance
physical performance.
23 Still another object of the invention is a method for promoting weight
control, weight
24 loss, enhanced physical performance, and/or the addition of lean muscle
mass which includes
ao
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 the step of administering to a subject an effective amount of at least one
of the group of five
2 adrenergic amines.
s Another object of the invention is to obtain the adrenergic amines from the
plant
material of the genus Citrus, and more specifically from the leaves, bark,
unripe fruit, ripe fruit
s and peel of the species Citrus aurantium and/or Citrus reticulate.
6 In achieving the above and other objects, one feature of the invention is
that the
composition can be administered in the form of the plant material in a tablet,
capsule or other
pharmacologically appropriate carrier, in the form of a tea, or in the form
without plant
9 material in a tablet, capsule or other pharmacological carrier which
contains at least one of the
1 o group of five adrenergic amines extracted from the plant material.
m DESCRIPTION OF DRAWINGS
12 Figure I shows the chemical structures of the five alkaloids: synephrine,
hordenine,
z 3 octopamine, tyramine and N-methyltyramine.
14 DETAILED EMBODIMENTS OF THE INVENTION INCLUDING BEST MODE
15 It has now surprisingly been found that agents present in plants other than
16 Ephedraceae may also act as sympathicomimetic agents with suitable
mechanisms of action in
m the body, and use of these plants can therefore result in benefits as
outlined with regard to
1 s body weight regulation and physical performance.
19 The value of the use of such plants in body weight regulation and physical
performance
2 o has not been suspected prior to this invention. Though the plants
concerned have
21 acknowledged uses and long histories as foods, they have not been used to
induce v~ieight loss
22 or for ergogenic purposes. The agents these plants contain have likewise
not previously been
23 related to weight loss or ergogenic applications. Furthermore, the agents
are generally only
24 present in significant amounts in parts of the plant which are considered
as inedible waste for
2 s normal consumption, or are only present during certain stages of the
growth cycle when the
al
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
plant would not normally be consumed. While it is true that the plants or
their parts harvested
2 during a particular stage of growth have also been used as medicinal herbs
or traditional
3 remedies, particularly in the Orient, these uses have also not included
applications in either
4 weight loss or for ergogenic purposes, and the uses according to the
invention are therefore
novel and surprising.
6 The agents contained in the plants which are used in accordance with the
invention
include synephrine, hordenine, octopamine, tyramine and N-methyltyramine, and
they may be
s found in various species of plants, both food plants and otherwise, as
detailed by Wheaton and
Stewart ( 1970), including, but not limited to, Amaryllidaceae, Leguminosae,
Liliaceae,
1 o Rutaceae, Cyperaceae, Solanaceae and Berberidaceae. Figure 1 shows the
chemical structures
1 Z of synephrine, hordenine, octopamine, tyramine and N-methyltyramine.
i2 However, in terms of practical utility, the levels of these agents
generally only reach
13 useful values, that is to say levels in excess of 0.1 % of dry mass, in
certain species of
i 4 Rutaceae. Furthermore, these useful levels are only achieved during phases
of growth where
1 s the plant would not normally be used for food, or in parts of the plant
which are not
16 considered part of the edible portion such as the leaves. In particular,
relatively high levels of
m synephrine and related substances (such as octopamine, hordenine, tyramine
and
1 s N-methyltyramine) can be found in various Citrus species, including in
particular, but not
19 restricted to, strains of Citrus reticulata (also known as tangerine or
mandarin orange), Citrus
2 o aurantium (also known as C. florida, C. vulgaris, C. bigaradia, Sour
orange, Bitter orange,
21 Seville orange, Neroli orange), Citrus medica, Citrus maxima, Citrus limon,
Citrus
22 aurantiifolia, Citrus paradisi, Citrus sinensis and Poncirus trifoliate
(trifoliate orange).
2 s These various Citrus species have been used, and continue to be used, for
a variety of
2 4 food purposes and for their health benefits, but have hitherto not been
revealed as herbs or
2 s plants which have value in the treatment of weight problems or for
improving physical
as
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
s performance and fitness.
2 Herbs based on Citrus materials have long been used for a variety of
medicinal
3 applications unrelated to weight loss. In this respect, for example, the
literature discloses a
number of Oriental herbs for medicinal applications, including the following:
s Zhi shi: The immature (dried) fruit of Citrus aurantium is used for the
treatment of
6 digestive disorders, to induce diuresis, and as a mucolytic agent to relieve
chest congestion
(0u Ming, 1989). It may contain levels of the desired active agents of up to
0.9%. Reid
a ( 198G) describes Zhi shi as the unripe fruit of the trifoliate orange,
indicated for digestive
9 disorders and as an expectorant, while Huang ( 1993 ) implies that this herb
is derived from
1 o mature fruits of Citrus aurantium.
m Zhi Qiao: This herb is also the immature fruit of Citrus aurantium, and is
used to treat
i2 indigestion and to correct mild ptosis of the uterus (Huang, 1993). Levels
of active substances
i3 are similar to those in the herb Zhi shi, and the distinction between these
two herbs appears to
14 be based on degree of maturity (of the fruit) and the area in which
traditionally used.
15 Chen pi: The herb Chen pi is dried peel of Citrus reticulata. This may also
be called 3iu
16 Hong, and is used as a digestive aid, antiemetic, antitussive and
antiflatulant (Huang, op. cit.).
m The herb also has anti-infective properties (0u Ming, op. cit.).
is Qing pi: This herb is immature Citrus reticulata, or in some cases the peel
thereof. It is
19 used to treat digestive disturbances and to alleviate pain, as an
expectorant, and to relax
2o smooth muscle (0u Ming, op. cit.).
21 Fo Shou: Also known as Fructus Citri Sarcodactyli, the fruit of Citrus
medica var.
22 sarcodactylus, it is used for treatment of digestive disorders, for
dysmenorrhea, chest
2 s congestion and as an expectorant (0u Ming, op. cit. ).
24 According to Bown (1995), Citrus aurantium and Citrus reticulata are known
by
2 5 dii~erent Chinese names in part according to their uses. For example, the
whole fruit, peel,
a~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 unripe fruit, unripe peel and seeds of C. reticulata are referred to as
"Chen pi" ("dried ripe
2 peel") to treat indigestion, flatulence, vomiting and wet coughs, but as
"Qing pi" ("unripe
peel") when used to treat liver and gall bladder disorders, bronchial
congestion, mastitis,
4 breast cancer, and pain in liver, chest or breasts, while the form "Ju he"
(Jiu hong; normally
the seeds) is used to treat lumbago, orchitis and mastitis.
n In Western traditional medicine, Wichtl (1994) describes use of the mature
or
immature fruit of Citrus limon for the treatment of digestive problems and
phlebitis, and notes
s that the flowers of Citrus aurantium and occasionally Citrus sinensis are
also used for their
9 sedative effects. Wichtl also reports that dried peel of Citrus aurantium,
or the dried whole
1 o immature fruit, is used in gastrointestinal remedies, tonics, roborants
and cholagogues. Grieve
m (1992) describes use of lemon juice for the treatment of rheumatism, and of
the oils from
12 various oranges for alleviation of chronic bronchitis. Font Quer (1982)
refers to the
1 s antispasmodic and hypnotic properties of Citrus aurantium flowers, and to
the use of the dried
14 peel as a gastric tonic and antiflatulant.
Numerous other standard textbooks of herbology refer to Citrus material of
various
16 types and its use for the alleviation of gastric disorders. However,
neither the use of such
1 ~ materials to induce weight loss nor their use to increase physical
performance or muscle mass
1 s are described, and these uses are therefore surprising, novel and not
anticipated.
19 The active agents synephrine, hordenine, octopamine, tyramine and N-
methyltyramine
2 o are known to be adrenergic agents, and synephrine is still used under the
synonym oxedrine in
21 some countries for the treatment of hypotension (Reynolds, 1982). However,
apart from
z2 occasional use of tyramine as a diagnostic agent in suspected cases of
phaeochromocytoma,
23 their use has been abandoned in favor of newer, synthetic adrenergic
agents, and no indication
24 of their value in weight loss or physical performance can be found in the
literature. Their
valuable properties in these respects are therefore unanticipated, surprising
and novel.
a~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 The Citrus material used in accordance with the invention may consist of any
portion
2 of the plant which contains useful amounts of the agents as defined above,
which may vary
s depending on the species, stage of growth, season, and agronomic conditions.
For example,
4 leaves of Citrus reticulate are preferred to other parts of this plant, and
may show levels of
s synephrine and related alkaloids of 1.1 % or more, based on dry matter,
while the peel of the
immature fruit shows levels of only 0.2% - 0.4%. In the case of Citrus
aurantium, the
preferred form is the whole immature fruit of the amara variety, though the
peel of the mature
a fruit can also be used. In both Citrus aurantium cases, total levels of 0.2%
- 0.9% of
9 synephrine and the related agents are regularly found. Both the peel and the
whole fruit
l o (immature or mature) of the dolce variety also have utility, though levels
generally do not
11 exceed 0.4%.
i2 Though it is possible to use a variety of Citrus materials in accordance
with the
is invention, it is more convenient to utilize Citrus materials which already
exist in appropriate
14 form and which are generally available as traditional herbs and remedies.
For example, the
is agents are present in the residues remaining after steam distillation of
Citrus aurantium fruits
16 to obtain the essential oils. In this respect, various Chinese herbs, or
materials from other
1 ~ geographic locations prepared in the same way, are particularly useful, as
are Citrus reticulate
18 leaves.
19 The Chinese herbs which are most convenient for use are:
2 0 o Zhi shi, which is the immature (dried) fruit of Citrus aurantium, but
may also
21 consist of the peel of the mature fruit, or the peel of either. This herb
contains 0.2% - 0.9%
2 2 total alkaloids with synephrine predominating.
23 o Zhi Qiao, which is also the immature fruit of Citrus aurantium has levels
of
24 active substances similar to those in the herb Zhi shi.
25 o Chen pi, the dried peel of Citrus reticulate, may also be called Jiu
Hong. This
a~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96116213
1 herb contains 0.1 % - 0.4% total alkaloids.
2 o Qing pi is the dried immature Citrus reticulata, or in some cases the peel
s thereof. This herb contains 0.1% - 0.4% total alkaloids.
o Fo Shou, also known as Fructus Citri Sarcodactyli, is the fruit of Citrus
medica
s var. sarcodactylus. This herb contains 0.1% - 0.3% total alkaloids.
In addition to the above, peel of the mature or immature fruit of Citrus limon
may
conveniently be obtained, since it is also an item of commerce, while
tangerine leaves are also
a readily obtained at certain seasons.
9 In a preferred embodiment of the invention, therefore, material from Citrus
species is
1 o given to humans by the oral route, either concurrently with caloric
restriction or in the absence
11 Of caloric restriction, for the purpose of controlling body weight. The
invention works
12 predominantly by increasing thermogenesis, that is, by increasing the
metabolic rate and
13 facilitating lipolysis. The invention also exhibits a hunger-suppressing
effect which may
z 4 become more obvious in higher doses as well as in individuals in which the
active agents pass
15 the blood-brain barrier more readily. Thus, most ~ users will benefit
mainly from the
16 thermogenic effect and additionally may also experience mild suppression of
hunger such that
1 ~ both mechanisms operate simultaneously, thereby providing an added
benefit. In addition, the
1 s said material can be given to humans, either with or without a high
protein diet (> 1.25 gm
protein/kg ideal body weight/day), for the purpose of increasing physical
performance in the
2 o short-term and to increase muscle mass and functionality in the long term.
2 s The Citrus material so used is selected for its content of active agents
as defined above
22 such that the total amount of Citrus material ingested provides a
sufficient amount of the
z 3 active agents to achieve the desired effects. In this respect, the
preferred embodiment
2 4 consisting of a sufficient amount would be defined as at least 0.04 mg of
active agents per
2s kilogram ideal body weight per dose at any one time. In practical terms
this corresponds to
a~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
z 2.8 mg for a person of 70 kg ideal body weight.
2 Ingestion of active agents in the range of 0.01 mg to 0.10 mg per kilogram
of ideal
3 body weight per serving will be effective in accomplishing the desired goal
of weight loss,
4 though more preferred is a range of 0.02 mg to 0.06 mg per kilogram of ideal
body weight,
s and most preferred is 0.05 mg per kilogram of ideal body weight. Though
ingestion of larger
amounts of the agents will not diminish the beneficial effects, the effects
may not necessarily
be increased while the possibility of side-effects due to activation of other
adrenergic systems
would be increased. Thus, at an intake level of 1 mg per kilogram of ideal
body weight per
9 serving, it is possible that the adrenergic receptors in the cardiovascular
and central nervous
1 o system could be activated thereby resulting in increases in blood pressure
as well as
11 tachycardia, nervousness, agitation, tremors, and insomnia.
12 Daily intake of the active agents for effective body weight loss according
to the
13 invention is in the range of 0.16 mg to 1 mg per kilogram of ideal body
weight. Thus, an adult
14 male whose desired body weight is 176 pounds would lose weight according to
this invention
with servings of 4 mg, with total daily intake in the amount of 32 mg.
i 6 In this context, the active agents are deemed to be any one or more of
synephrine,
1~ hordenine, octopamine, tyramine and N-methyltyramine, whereby the su~cient
amount may
1 a be any one singly, or a combination of the agents that together provide a
sufficient amount.
19 Because levels of the said agents are often relatively low and variable,
and also because
2 o in their natural state the agents are associated with parts of the plant
that are unpalatable, it
2s may be diffcult to achieve an intake of Citrus material in a volume
sufficient to provide a
22 suitable amount of the agents as defined above.
2 s To enhance edibility, the Citrus material may be consumed as a concentrate
or as an
2 4 extract in either dry or liquid form. By producing a concentrate or
extract, the levels of the
2 s agents in the material are increased to an effective level. There are
several ways readily known
a~
CA 02248854 1998-08-31
WO 98/14200 PCT/LTS96/16213
1 to those schooled in the art which permit production of a concentrate or
extract. The Citrus
2 material may be enriched in the agents, for example, by extraction of the
Citrus material with
water, dilute acids or certain organic solvents, including mixtures thereof
with water, followed
by drying on a carrier of unconcentrated Citrus material, or by drying on a
carrier of another
s suitable material. Such a suitable material may include, but is not limited
to, maltodextrins,
E starch, protein or other carrier material, the nature of which will be
obvious to those skilled in
the art of manufacturing extracts of botanical materials. The Citrus material
may also be
s extracted and concentrated without drying to give a liquid extract that can
also be consumed.
When prepared as an extract or concentrate, the Citrus material is preferably
dried so
1 o that it may be given in the form of tablets, capsules, powders or other
convenient form, or it
11 may be admixed with foods or special food products, or it may be given in
the form of a tea or
i2 tisane. When prepared as a liquid extract, the Citrus material may be
consumed as drops, or
13 from an appropriate liquid measure (teaspoon), or it may be admixed with
other liquids or
z 4 incorporated into solid food products. Preparation as an extract or
concentrate permits
15 production of standardized amounts of the active agents so as to produce a
less variable
16 response in terms of desired weight loss and/or the desired increase in
muscle mass.
If it is not prepared as an extract or concentrate, the Citrus material may be
given
18 fresh, but is preferably dried so that it may be given in the form of
tablets, capsules, powders
z 9 or other convenient form, or it may be admixed with foods or special food
products, or it may
2 o be given in the form of a tea or tisane.
21 For example, the dried leaves of Citrus reticulata var. Blanco may be
filled into tea
22 bags to give a refreshing vitalizing drink that enervates and suppresses
hunger for long
2 3 periods, while dried immature fruits of Citrus aurantium var. amara are
best milled to a fine
2 4 powder and either tabletted or filled into capsules for repeated oral
administration to achieve
2 s similar effects over a period of weeks or months.
a~
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 The Citrus materials may also be admixed with other ingredients to form the
basis of a
2 dietary product, which may either be a nutritional drink or a nutritional
bar. One such
nutritional bar can provide 1 S grams of protein, 26 grams of carbohydrate and
5 grams of fat
4 in addition to a quantity of the Citrus material. Such products may thus be
used as meal
replacements by those seeking to lose weight, or by those requiring
nutritional support during
6 sporting activities, whereby the benefits of the Citrus material are
supported by the nutritional
content of the food product.
s The Citrus material, either in the form of an extract or as the natural
material, may also
9 be given in combination with other herbs that possess beneficial effects for
humans, and
1 o particularly in respect to weight loss or improvements in physical
performance. In this
11 connection, suitable herbs and foods include those herbs and foods that
contain
12 methylxanthines such as caffeine, theobromine and theophylline, which by
virtue of their
Z 3 inhibition of the enzyme phosphodiesterase may potentiate the thermogenic
actions of the
14 Citrus materials and increase the actions at the level of the beta-3-
receptors. At the same time,
is the actions of methylxanthines on alpha-receptors may serve to reduce or
eliminate any
16 unwanted cardiovascular effects, such as peripheral vasoconstriction and
increase in blood
17 pressure, that would be undesirable within the context of weight loss or
improved physical
1e performance. Suitable herbs and foods in this respect include, but are not
limited to, Paullinia
19 cupana (Guarana), Ilex paraguariensis (Mate), Cola nitida, Cola acuminata,
Camellia sinensis
20 (Tea), Coffea arabica (Coffee) and Theobroma cacao (Cocoa), whereby the
herb or food may
2 s be .used as the natural material or an extract thereof. In such cases, the
herb so chosen is
22 admixed with the Citrus material in a suitable form to provide a solid or
liquid dosage unit.
23 The invention is further exemplified and illustrated by the following
examples which
24 are not limiting.
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
1 Example 1:
2 Tea-bags containing each 2.5 grams dried tangerine leaves (Citrus reticulata
var.
Blanco) were prepared. The tangerine leaves had a synephrine content of 1.1%
and
approximately 0.5% of the related alkaloids, which did not resolve completely
on HPLC
s analysis, thus providing a total amount of 40 mg of alkaloids per serving.
The tea bags were
infused for 5 minutes in hot water at 85°C, and the resulting tisane
was given to 5 volunteers
(GL, RE, NS, CS, PS). All volunteers reported increased energy, which in one
case was
a perceptible as agitation and nervousness, persisting for 8 - 10 hours.
During this period,
9 subjects did not feel hungry and refrained from eating snacks or meals.
1 o Example 2:
m A Zhi shi powder (Citrus aurantium, var. amara, whole immature fruit dried)
was
12 obtained from a Chinese source. This powder contained 0.49% synephrine and
approximately
i3 0.5% of the related alkaloids. It was mixed with 2% magnesium stearate and
1°io silicon
14 dioxide to confer flowabilit~~ and filled into white size 0 snap-fit
capsules. Capsule fill weight
15 was 490 mg, plus or minus 5°,~. Subjects DJ and HAF then took 3
capsules 3 times daily for
16 four weeks, corresponding to an intake of 14 mg total alkaloids per
serving, or 42 mg per day,
m without deliberate restriction of food intake. Subject DJ, initial weight
105.4 kg, showed a fall
1 s in body weight to 100.9 k~;, while the body weight decrease in subject HAF
was from 74.5 kg
19 to 72.0 kg. Upon ceasing use of capsules, subjects showed slow increases in
body weight at a
2 o rate of approximately 0.4 kg per week.
21 Example 3:
22 A portion of the Zhi shi powder used in Example 2 was concentrated by
extraction
2 3 with water and redrying on a portion of the original material to give a
dry extract with a total
2 9 alkaloid content of 3.77%, of which approximately 1.9% was synephrine
itself. This material
2 s was filled into capsules as in Example 2 to provide a product with 18 mg
alkaloids of the
~d
CA 02248854 1998-08-31
WO 98/14200 PCT/US96116213
1 synephrine group per capsule. Subjects DJ and HAF then took I capsule of
this product 3
2 times daily for four weeks, providing a daily intake of 54 mg synephrine and
related alkaloids.
3 During this time, subject DJ, without deliberate restriction of food intake,
showed a decrease
9 in weight from 93.2 kg to 90.4 kg, but subject HAF had to cease use after
the first day
s because of unpleasant sensations of agitation and nervousness.
6 Example 4:
Two batches of nutrition bars were prepared using the Thermobar concept, that
is,
a chocolate-flavored taffy bars weighing 57 grams providing 15 grams protein,
26 grams
9 carbohydrate, 5 grams fat and 200 kilocalories. One batch of the bars
additionally contained
l0 0.5 grams of the extract from Example 3 per bar. Subject RE was given two
of the placebo
m bars. Respired gases were collected by the Douglas bag technique starting 30
minutes before
12 ingestion of the bars and for a 90 minute period thereafter. The
respiratory quotient (RQ) was
13 initially 0.78 and rose to 0.86 during the GO minutes after bar
consumption. Two days later
14 following the identical protocol, the subject consumed two of the bars
containing the Zhi shi
extract, corresponding to about 38 mg of synephrine and related alkaloids;
respiratory quotient
16 rose from 0.77 to 0.89 during the 60 minutes after bar consumption.
Conversion of these
1 ~ results of indirect calorimetry to energy expenditure showed that the Zhi
shi extract had
1 a increased the energy expenditure and the thermic response to the food by
about 2.5%, thus
19 indicating a thermogenic effect of the ingested alkaloids.
2 o Example 5
21 A group of 9 women, of whom 6 were mildly obese, 1 moderately obese and. 2
slightly
22 overweight, with Body Mass Indices ranging from 23.1 to 33.4 were placed on
a diet
23 providing 900 - 1000 kilocalories per day, more than 100 g protein per day
and less than I00 g
24 carbohydrate per day. From day 8 of this dietary regime, they were
additionally given a
3~
CA 02248854 1998-08-31
WO 98/14200 PCT/U896/16213
1 product in capsules identified as "Herbal Balance Z-4", providing each 325
mg of a dried
2 Citrus aurantium (immature whole fruit) extract, 125 mg of a dried Paullinia
cupana extract, 5
s mg of Ginkgo biloba extract and 5 mg Panax ginseng extract. They were
instructed to take 1 -
4 3 capsules 1 - 3 times per day, and to remain at a comfortable intake level
within these
s parameters; 2 subjects stabilized at 2 capsules per day, 2 at 3 capsules per
day, 2 at 4 capsules
per day and 3 at 5 capsules per day. The Citrus aurantium extract contained
4.14% total
alkaloids by HPLC, with approximately 2.8% as synephrine itself. The daily use
recorded thus
s corresponds to a total alkaloid intake of 27.0 to 67.5 mg.
9 Starting weights, weights at day 8, and weights at day 15 were determined.
In
1 o addition, each subject completed a daily mood, appetite and satiety rating
questionnaire.
1 ~. Subject Age: Height BMI: Weights (kg):
z2 (m) Day 0 Day 8 Day 15
is HS 38 1.57 24.9 61.4 60.5 57.3
14 GA 40 1.67 29.7 82.7 81.6 80.0
15 CB 25 1.65 23.1 62.7 62.7 60.0
16 CA 46 1.61 26.7 69.1 68.2 64.5
LG 30 1.60 25.7 65.8 64.5 62.8
1s AW 41 1.64 33.4 90.1 88.6 85.4
19 AEM 31 1.67 23.8 66.6 65.4 64.1
2 o CRT 23 1.73 25.9 77. 5 76.8 74.5
2 ~. LB 29 1.62 26.0 68.2 67.3 65.4
22 A statistical analysis showed a mean of 0.94 kg during the first week when
no product
2 3 was given and 2.40 kg during the second week when product was taken, the Z-
4 product
2 4 significantly increased weight loss (P < 0.05) during the second week.
CA 02248854 1998-08-31
WO 98/14200 PCT/US96/16213
i STATISTICAL ANALYSIS
2 Means t standard deviations:
3 Body Weight (kg) Weight Loss (kg}:
Day 0 71.57 ~ 9.75
Day 8 70.62 ~ 9.54 0.94 ~ 0.43
Day 15 68.22 ~ 9.54 2.40 ~ 0.84
Fuli data on body weight indicated:
a Day: Mean: SD: Median: Minimum: Maximum:
0 71.57 9.75 68.20 61.40 90.10
l 0 8 70.62 9.54 67.30 60.50 88.60
i1 15 68.22 9.54 64.50 57.30 85.40
i2 Full data on weight loss indicated:
13 Day: Mean: SD: Median: Minimum: Maximum:
i 9 8 0.94 0.43 0.90 0.00 1. 50
15 2.40 0.84 2.30 1.30 3.70
16 This result is particularly interesting, since part of the observed weight
loss during the
m first week was due to water loss as a result of changes in electrolyte and
water balance
1 s (adaptation to reduced caloric intake).
19 The foregoing description represents the best mode presently known to the
inventor of
2 o practicing the invention, and is not intended to limit the scope of the
present invention which is
21 set forth in the following claims. Likewise, those skilled in the art,
given the present
22 disclosure, will recognize that equivalent methods and materials may also
be used in practicing
2 s the invention. It is contemplated that such equivalents are also within
the scope of the present
2 4 lnventlon.
